Sartorius Stedim Biotech (DIM) AI Stock Analysis

• Market Cap: €17.46B
• Dividend Yield: 0.31%
• Average Volume (3M): 78.09K
• Price to Earnings (P/E): 65.7
• Beta (1Y): 1.31
• Revenue Growth: 7.72%
• EPS Growth: 53.84%
• Country: FR
• Employees: 9,961
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 1.12
• Shares Outstanding: 97,330,410
• 10 Day Avg. Volume: 78,938
• 30 Day Avg. Volume: 78,094
• PEG Ratio: 1.51
• Price to Book (P/B): 5.00
• Price to Sales (P/S): 6.89
• P/FCF Ratio: 140.53
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €235.86
• Price Target Upside: 29.59% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 7
• EPS Forecast (FY): 5.05
• Revenue Forecast (FY): €3.20B

• Rating: 52 Neutral
• Price Target: €185.00 ▲(1.65% Upside)
• Action: Reiterated Date: 02/22/26
• Date: Action: Reiterated 02/22/26

The score is driven primarily by mixed financial performance: strong TTM revenue rebound and improved profitability/leverage are offset by weak cash conversion and declining free cash flow. Technical signals are also a headwind with price below key moving averages and negative MACD. Valuation further pressures the score due to a high P/E and minimal dividend yield.

Positive Factors

Recurring revenue from consumables & services

A large share of sales comes from consumables and services, creating durable annuity-like revenues and customer stickiness. Over the next 2–6 months this supports revenue visibility and predictable cash inflows, helping fund R&D and operations despite equipment cyclicality.

Integrated solutions and market leadership

Leadership in integrated bioprocess systems and single-use technologies yields strong competitive advantages: high switching costs, cross-sell potential, and deep pharma partnerships. These structural advantages sustain market share and long-term demand in growing biologics segments.

Revenue rebound and improved leverage

A sharp TTM revenue recovery with rising margins and materially better leverage indicates operational recovery and a stronger earnings base. Improved balance-sheet metrics increase strategic flexibility to invest or execute M&A over a multi-month horizon.

Negative Factors

Weak free cash flow and cash conversion

Significantly weaker FCF and low cash conversion reduce internally available funds for capex, dividends, and acquisitions. Over 2–6 months this constrains financial flexibility and heightens dependence on external financing for growth initiatives or unexpected needs.

Margins well below prior peak and volatile

Persistent margin gap versus prior peaks and recent volatility suggest structural mix, pricing, or cost pressures. Lower sustainable margins constrain long-term returns and limit the company's ability to convert revenue gains into durable profit expansion.

High absolute debt burden

Elevated absolute debt increases interest and refinancing risk and reduces capacity for large discretionary spending. Even with better ratios, high nominal leverage limits resilience in downturns and can impede strategic agility over the medium term.

Sartorius Stedim Biotech Business Overview & Revenue Model

Company Description

Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, filtration, purification, and fluid management services; single-use and reusable hollow-fiber membrane devices, as well as presterilized assemblies for cell and gene therapy applications; and cell harvesting and various other solutions for intensified bioprocesses. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production. It serves manufacturers of pharmaceuticals, foods, and chemicals, as well as research and development laboratories. The company was founded in 1870 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.

How the Company Makes Money

Sartorius Stedim Biotech generates revenue through several key streams, primarily by selling bioprocessing equipment, consumables, and services to the pharmaceutical and biotechnology sectors. The company’s revenue model is heavily reliant on the sale of single-use technologies, fermentation systems, and filtration products, which are essential in the production of biologics. Furthermore, Sartorius benefits from long-term partnerships with major pharmaceutical companies, providing them with tailored solutions that enhance production efficiency and compliance. The recurring revenue from consumables and services, including maintenance and technical support, also contributes significantly to its earnings. The company's strategic investments in research and development help maintain its competitive edge, while acquisitions of complementary businesses further expand its market reach and product offerings.

Sartorius Stedim Biotech Financial Statement Overview

Summary

Revenue rebounded sharply in the TTM period and profitability improved versus 2024, with leverage also better than 2023. However, margins remain far below the 2021–2022 peak and free cash flow weakened materially with low cash conversion (FCF ~40% of net income), keeping overall financial quality mid-range.

Income Statement

TTM (Trailing-Twelve-Months) revenue rebounded sharply (+70.9%), and profitability improved versus 2024 (net margin ~8.9% vs ~6.3%). However, margins remain well below the 2021–2022 peak period (2022 net margin ~25.1%), and the multi-year trend shows meaningful volatility after the 2023–2024 slowdown.

Balance Sheet

Leverage looks more manageable than 2023, with debt-to-equity improving to ~0.64 in TTM (Trailing-Twelve-Months) from ~1.40 in 2023, supported by a larger equity base. That said, absolute debt remains high (~2.75B), and return on equity is modest in TTM (~6.6%), signaling profitability has not fully recovered relative to the capital employed.

Cash Flow

Cash generation is the key soft spot: TTM (Trailing-Twelve-Months) free cash flow fell materially (free cash flow growth ~-33.9%) and is low relative to earnings (free cash flow at ~40% of net income). Operating cash flow coverage also weakened versus 2024, pointing to less efficient conversion of profits into cash despite the top-line rebound.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	2.97B	2.78B	2.78B	3.49B	2.89B
Gross Profit	1.35B	1.21B	1.23B	1.82B	1.55B
EBITDA	867.10M	670.50M	755.70M	1.33B	811.96M
Net Income	265.60M	175.10M	309.70M	876.10M	414.40M
Balance Sheet
Total Assets	8.02B	8.26B	7.74B	5.07B	3.95B
Cash, Cash Equivalents and Short-Term Investments	426.10M	688.80M	126.10M	133.00M	237.35M
Total Debt	2.75B	2.87B	3.68B	1.14B	625.52M
Total Liabilities	3.89B	4.23B	5.07B	2.55B	2.22B
Stockholders Equity	4.09B	3.99B	2.64B	2.45B	1.66B
Cash Flow
Free Cash Flow	145.40M	475.30M	156.10M	181.70M	371.98M
Operating Cash Flow	538.60M	815.10M	629.70M	612.30M	695.97M
Investing Cash Flow	-397.70M	-340.00M	-2.72B	-957.50M	-465.23M
Financing Cash Flow	-389.20M	84.90M	1.99B	220.70M	-69.27M

Sartorius Stedim Biotech Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 182.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:DIM, the sentiment is Neutral. The current price of 182 is above the 20-day moving average (MA) of 178.88, below the 50-day MA of 196.88, and below the 200-day MA of 192.34, indicating a neutral trend. The MACD of -4.96 indicates Negative momentum. The RSI at 46.86 is Neutral, neither overbought nor oversold. The STOCH value of 79.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for FR:DIM.

Sartorius Stedim Biotech Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VIRP	75 Outperform	€3.09B	23.23	12.92%	0.41%	6.97%	-5.59%
IPN	67 Neutral	€13.21B	29.76	10.82%	1.17%	9.57%	-34.30%
BIM	66 Neutral	€11.28B	29.82	9.69%	0.82%	8.28%	-8.08%
SAN	66 Neutral	€97.64B	18.91	8.39%	4.77%	-9.82%	119.10%
ERF	64 Neutral	€12.16B	25.31	11.27%	0.97%	6.25%	18.93%
DIM	52 Neutral	€17.46B	65.70	6.65%	0.31%	7.72%	53.84%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%